Anitha Anne

Cooley advised the underwriters of Silvaco, a leading provider of technology computer-aided design (TCAD), electronic design animation (EDA) software, and session initiation protocol (SIP) solutions that enable semiconductor design and artificial intelligence through software and innovation, on its $114 million initial public offering.

Cooley advised Carmot Therapeutics, a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes, on its definitive merger agreement in which Roche will acquire Carmot.

Cooley advised Turnstone Biologics, a clinical-stage biotechnology company, on its upsized $80 million initial public offering.

Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.

Cooley advised AN2 Therapeutics on its $79 million initial public offering of 4,600,000 shares of common stock at a price to the public of $15.00 per share. AN2 is a clinical-stage biopharmaceutical company developing treatments for rare, chronic and serious infectious diseases with high unmet needs. Partner Josh Seidenfeld, associate Anitha Anne and Sally Kay of counsel led the Cooley team.